Bone marrow niches in haematological malignancies
Haematological malignancies were previously thought to be driven solely by genetic or
epigenetic lesions within haematopoietic cells. However, the niches that maintain and …
epigenetic lesions within haematopoietic cells. However, the niches that maintain and …
Adult haematopoietic stem cell niches
Stem cell niches are specialized microenvironments that promote the maintenance of stem
cells and regulate their function. Recent advances have improved our understanding of the …
cells and regulate their function. Recent advances have improved our understanding of the …
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
A Aguayo, H Kantarjian, T Manshouri… - Blood, The Journal …, 2000 - ashpublications.org
Angiogenesis has been associated with the growth, dissemination, and metastasis of solid
tumors. The aims of this study were to evaluate the vascularity and the levels of angiogenic …
tumors. The aims of this study were to evaluate the vascularity and the levels of angiogenic …
Myeloid malignancies and the microenvironment
C Korn, S Méndez-Ferrer - Blood, The Journal of the American …, 2017 - ashpublications.org
Research in the last few years has revealed a sophisticated interaction network between
multiple bone marrow cells that regulate different hematopoietic stem cell (HSC) properties …
multiple bone marrow cells that regulate different hematopoietic stem cell (HSC) properties …
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
K Podar, KC Anderson - Blood, 2005 - ashpublications.org
Besides its role as an essential regulator of physiologic and pathologic angiogenesis,
vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of …
vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of …
Differentiation and expansion of endothelial cells from human bone marrow CD133+ cells
N Quirici, D Soligo, L Caneva, F Servida… - British journal of …, 2001 - Wiley Online Library
We report a method of purifying, characterizing and expanding endothelial cells (ECs)
derived from CD133+ bone marrow cells, a subset of CD34+ haematopoietic progenitors …
derived from CD133+ bone marrow cells, a subset of CD34+ haematopoietic progenitors …
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients
P Mancuso, A Burlini, G Pruneri… - Blood, The Journal …, 2001 - ashpublications.org
Circulating endothelial cells (CECs) were enumerated in 20 healthy controls and 76 newly
diagnosed cancer patients by means of 4-color flow cytometry. In breast cancer (n= 46) and …
diagnosed cancer patients by means of 4-color flow cytometry. In breast cancer (n= 46) and …
Vascular endothelial growth factor (VEGF)–C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy
Similar to solid tumors, growth of leukemias may also be angiogenesis dependent.
Furthermore, tyrosine kinase receptors specific to endothelial cells are expressed on certain …
Furthermore, tyrosine kinase receptors specific to endothelial cells are expressed on certain …
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in …
WT Bellamy, L Richter, D Sirjani… - Blood, The Journal …, 2001 - ashpublications.org
Vascular endothelial growth factor (VEGF) is a potent angiogenic peptide with biologic
effects that include regulation of hematopoietic stem cell development, extracellular matrix …
effects that include regulation of hematopoietic stem cell development, extracellular matrix …
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
A Raza, P Meyer, D Dutt, F Zorat, L Lisak… - Blood, The Journal …, 2001 - ashpublications.org
Thalidomide was administered to 83 patients with myelodysplastic syndrome (MDS), starting
at 100 mg by mouth daily and increasing to 400 mg as tolerated. Thirty-two patients stopped …
at 100 mg by mouth daily and increasing to 400 mg as tolerated. Thirty-two patients stopped …